Regulatory Action and Cancellation On August 28, the Karnataka Food Safety and Drug Administration (FDA) officially cancelled the proposed Peptide Party event slated for August 29 in Koramangala, Bengaluru. The decision came after the FDA issued a notice to Upsurge Labs LLP, the event organiser, demanding comprehensive details about the peptide preparations that were to be promoted, supplied, or administered at the gathering.
The FDA’s public advisory clarified that the cancellation was not a punitive measure but a precautionary step pending the review of the information submitted by Upsurge Labs. The department urged the public to stay informed about the development and highlighted that the event had been called off following the regulator’s request for clarification.
Details Requested by Karnataka FDA The notice, dated August 27, outlined a meticulous list of data required from Upsurge Labs. This included product and brand names, composition, dosage forms, route of administration, batch and lot numbers, manufacturing licences, import documents, and evidence of regulatory approvals. The regulator specifically requested scientific backing for any therapeutic claims related to weight management, muscle growth, anti‑ageing, metabolic health, and athletic performance.
Additionally, the FDA sought information on the personnel who would administer the preparations, their qualifications, and the protocols for consent, medical supervision, and emergency management. Upsurge Labs was given a deadline of August 28 at 10:30 AM to submit authenticated copies of all relevant documents and to preserve related records such as invoices, purchase orders, promotional material, and social media posts.
The FDA’s inquiry underscores the stringent regulatory framework governing peptide preparations under the Drugs and Cosmetics Act, 1940, and the New Drugs and Clinical Trials Rules, 2019. The regulator remains vigilant about potential violations, including the sale of unlicensed products or the promotion of unapproved indications. The outcome of this investigation will set a precedent for how peptide‑based wellness events are regulated in Karnataka and across India.